As reported in the British Medical Journal (BMJ), Prescrire are being sued by the manufacturer of tacrolimus ointment (Protopic®).
Prescrire has reviewed the drug several times and classified is as "not acceptable" based on the conclusion that the product is "without evident benefit but with real or potential disadvantages". This is based upon reports of skin irritation, infection and skin cancer, all of which are known and documented side effects. Prescrire were also highly critical of a licence extension covering maintenance use.
Action: The verdict in this case is due by the end of this month. Clinicians may wish to be aware of this case and the impact it may have on future drug reviews in medical journals and other healthcare organisations.
|« Vascular benefits of statins and CRP||Humulin and Humalog pens replaced »|